Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXIR: Efficacy and Safety of XyloCore for Peritoneal Dialysis
NCT03994471Phase 3Recruiting
- Sponsor
- Iperboreal Pharma
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 6
01
Overview
A Phase 3 trial of encoberminogene rezmadenovec in end stage renal disease (ESRD), sponsored by Iperboreal Pharma. Started Dec 2022; status: recruiting.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03994471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994471.